AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.530
+0.010 (0.28%)
At close: Mar 19, 2026, 4:00 PM EDT
3.590
+0.060 (1.70%)
After-hours: Mar 19, 2026, 7:58 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 4 analysts that cover AbCellera Biologics stock have a consensus rating of "Strong Buy" and an average price target of $7.75, which forecasts a 119.55% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $10.
Price Target: $7.75 (+119.55%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | +13.31% | Nov 7, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +98.30% | Aug 8, 2025 |
| Keybanc | Keybanc | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +183.29% | Jul 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $5 | Buy | Initiates | $5 | +41.64% | Jul 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $28 → $10 | Strong Buy | Maintains | $28 → $10 | +183.29% | May 16, 2025 |
Financial Forecast
Revenue This Year
31.68M
from 75.13M
Decreased by -57.83%
Revenue Next Year
36.94M
from 31.68M
Increased by 16.59%
EPS This Year
-0.77
from -0.49
EPS Next Year
-0.82
from -0.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 60.9M | 72.5M | |||
| Avg | 31.7M | 36.9M | |||
| Low | 19.5M | 25.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -18.9% | 128.7% | |||
| Avg | -57.8% | 16.6% | |||
| Low | -74.0% | -21.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.63 | -0.63 | |||
| Avg | -0.77 | -0.82 | |||
| Low | -0.94 | -0.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.